Fundraising FoxDomain Partners — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)
BoardJustin Klein(Director)in
Board seatJames C. Blair· per SEC Form D · $12.1M raise · filed Apr 2017
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Associates+2 more
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardEckard Weber(Director)
Board seatBrian H. Dovey· per SEC Form D · $49.6M raise · filed Mar 2017
Co-investorsCross Creek AdvisorsMontreux Equity PartnersNew Enterprise Associates (NEA)Sofinnova VenturesDomain Associates
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.